Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2026 07:00 ET | Source: Castle Biosciences, Inc.

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Castle announced new data that confirm that the i31-SLNB accurately predicts SLN positivity and identifies low-risk patients who may safely forgo SLNB.
March 04, 2026 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

Castle will share new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
November 14, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.
April 30, 2025 17:00 ET | Source: Castle Biosciences, Inc.

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.
April 03, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced the recent publication of prospective data demonstrating the significant impact of DecisionDx-Melanoma on SLNB decision-making.